Cargando…

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells

Introduction: Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase exhibiting high affinity for reduced folate carrier-1 with antineoplastic and immunosuppressive activities, similar to methotrexate. Despite advances in multi-modality treatment strategies, the survival rates for ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clark, Rachael A., Lee, Sora, Qiao, Jingbo, Chung, Dai H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429182/ https://www.ncbi.nlm.nih.gov/pubmed/32850011 http://dx.doi.org/10.18632/oncotarget.27697

Ejemplares similares

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma
por: Kinahan, Cristina, et al.
Publicado: (2020)

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma
por: Qiao, Jingbo, et al.
Publicado: (2022)

Identification of α-N-catenin as a novel tumor suppressor in neuroblastoma
por: Qiao, Jingbo, et al.
Publicado: (2019)

Gli1 Transcriptional Activity is Negatively Regulated by AKT2 in Neuroblastoma
por: Paul, Pritha, et al.
Publicado: (2013)

Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma
por: Clark, Rachael A., et al.
Publicado: (2022)

FAK is a Critical Regulator of Neuroblastoma Liver Metastasis
por: Lee, Sora, et al.
Publicado: (2012)

High-Risk Neuroblastoma: A Surgical Perspective
por: Jacobson, Jillian C., et al.
Publicado: (2023)

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma
por: Kim, Kwang Woon, et al.
Publicado: (2019)

Akt2 Regulates Metastatic Potential in Neuroblastoma
por: Qiao, Jingbo, et al.
Publicado: (2013)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma
por: Paul, Pritha, et al.
Publicado: (2017)

Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
por: Jacobson, Jillian C., et al.
Publicado: (2022)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma
por: Rellinger, Eric J., et al.
Publicado: (2017)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Targeting Gastrin-Releasing Peptide Suppresses Neuroblastoma Progression via Upregulation of PTEN Signaling
por: Paul, Pritha, et al.
Publicado: (2013)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
por: Tedeschi, Philip M., et al.
Publicado: (2014)

Overexpression of microRNA-145 inhibits tumorigenesis through autophagy in chemotherapy and radiation resistant neuroblastoma cells
por: Kim, Kwang Woon, et al.
Publicado: (2020)

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma
por: Tang, Xao X., et al.
Publicado: (2022)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
por: Izbicka, E., et al.
Publicado: (2009)

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
por: Tedeschi, Philip M., et al.
Publicado: (2015)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment: Erratum
Publicado: (2020)

Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
por: Wolter, Jennifer K, et al.
Publicado: (2013)

Anti-tumor effect of Huaier extract against neuroblastoma cells in vitro
por: Xu, Dong-qing, et al.
Publicado: (2021)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6bglpopglfth1e9pofs9sam8pf